Merck shares are trading higher after the company announced the Phase 3 KEYNOTE‑C93 trial evaluating KEYTRUDA met its primary endpoint of progression-free survival.
Merck shares are trading higher after the company announced the Phase 3 KEYNOTE‑C93 trial evaluating KEYTRUDA met its primary endpoint of progression-free survival.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day